Hawthorn executes deal with university
MADISON — Hawthorn Pharmaceuticals Inc. has struck a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer.
Under the terms of the agreement, Madison-based Hawthorn will receive an exclusive worldwide license to develop and commercialize the antibody portfolio.
“We are excited to be working with the world=-class cancer scientists at University of Pittsburgh’s Cancer Institute who have devoted their entire careers to improving people’s lives through cancer discovery,” said Rob Lewis, chief scientific officer at Hawthorn.
“There are many strengths created by our relationship with the University of Pittsburgh that promotes the rapid development of these novel antibodies,” said Max Draughn, president and CEO of Hawthorn. “Our collaboration is a shared vision to ultimately extend and improve the lives of many children and adults who suffer with various cancers.”
To sign up for Mississippi Business Daily Updates, click here.
Top Posts & Pages
- DMR pays accounting firm more than double contract's worth
- Following ruling, Entergy to hand over records to county
- Chris McDaniel gets a thank you note from Travis Childers
- UPDATED: House subcommittee tosses discrimination elements from religious freedom bill
- Nehi Bottling Company has been a Cleveland fixture for 85 years
- Gulf Coast's design studio teaches lessons on sustainability
- Mississippi ag aviation plays a critical role in production and profitability
- Corps allots more funding to projects in Mississippi
- Senate passes teacher pay raise legislation